Clinical trial
Gamma-Amino Butyric Acid (GABA)-A Alpha2/3 Study
NCT00129441 · University of Pittsburgh, Other · Completed
Key facts
| NCT number | NCT00129441 |
|---|---|
| Title | Gamma-Amino Butyric Acid (GABA)-A Alpha2/3 Study |
| Official title | Treatment of Cognitive Disability in Schizophrenia With a GABA-A Alpha2/3 Receptor Agonist |
| Lead sponsor | University of Pittsburgh, Other |
| Collaborators | Merck Sharp & Dohme LLC Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | Merck L-830982, Placebo |
| Enrollment | 16 |
| Start date | Aug 1, 2005 |
| Primary completion | Jan 1, 2008 |
| Completion | Jan 1, 2008 |
| First posted | Aug 11, 2005 |
| Last update posted | Oct 17, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: